GSK and Amgen amend Prolia marketing agreement

Amgen and GSK have terminated their collaboration agreement for the promotion of Prolia (denosumab) for Osteoporosis indications for the EU, Switzerland, Norway, Russia and Mexico (except for Australia) and GSK activities for those countries will cease by 31 December 2024. GSK will retain the right to sell Prolia in China, Brazil, India and South Korea for uses beyond Osteoporosis until 2014. Prolia generated sales of $744 million in 2013. Up 58% on the previous year.